Beta Bionics, Inc. (BBNX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Beta Bionics, Inc. reported revenue of $100.25M, up 53.9% from the prior year. The company ran a net loss, with a net margin of -73.0% and a gross margin of 55.4%. It held $328.74M in total assets against $41.13M in total liabilities.
Key ratios (FY2025)
55.4%
Gross margin
-71.5%
Operating margin
-73.0%
Net margin
-25.5%
Return on equity
+53.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $100.25M | $65.12M | $11.99M | — |
| Cost of Revenue | $44.71M | $29.24M | $5.69M | — |
| Gross Profit | $55.54M | $35.89M | $6.31M | — |
| Operating Income | -$71.68M | -$45.25M | -$35.85M | — |
| Net Income | -$73.20M | -$54.76M | -$44.10M | — |
| EPS (Diluted) | $-1.81 | $-8.60 | $-8.31 | — |
| Total Assets | $328.74M | $149.65M | $110.04M | — |
| Total Liabilities | $41.13M | $73.63M | $51.43M | — |
| Shareholders' Equity | $287.61M | -$245.36M | -$203.10M | -$170.03M |
| Cash & Equivalents | $31.58M | $30.43M | $26.57M | — |
| Operating Cash Flow | -$50.92M | -$48.27M | -$32.45M | — |
| Capital Expenditures | $5.30M | $3.40M | $402.0K | — |
| Shares Outstanding | 40.53M | 6.37M | 5.30M | — |